Current use of a smoking cessation medication (e.g. nicotine replacement, varenicline, bupropion) Current use of a smoking cessation medication (e.g. nicotine replacement, varenicline, bupropion) Smoking (cigarettes, cigars or pipes) must be discontinued at least days prior to initiating study drug administration; smoking cessation products (transdermal nicotine patches or chewing gum may be used) Current enrollment or plans to enroll in another smoking cessation program in the next months Plan to use other nicotine substitutes (i.e., over-the-counter [OTC] or prescription medication for smoking cessation) or smoking cessation treatments in the next months Involved in current smoking cessation activity Smoking (cigarettes, cigars or pipes) must be discontinued at least days prior to initiating study drug administration; smoking cessation products (transdermal nicotine patches or chewing gum may be used. Currently enrolled in other professional tobacco cessation therapeutic intervention Current use of medications with smoking cessation efficacy Within the days before registration, no use of: ) any pharmacologic treatment for smoking cessation, including bupropion or nicotine replacement therapy; ) any nicotine delivery system (i.e., e-cigarettes and vape products); or ) be enrolled in any formal behavioral treatment program for tobacco dependence as determined by patient report KEY INFORMANT: Member of the lung cancer screening team who is (or would be) responsible for implementation and/or supporting smoking cessation support for patients receiving lung cancer screening; this will include the program champion (intervention clinic only) and is likely to include: imaging facility program directors, health care providers (e.g., physicians, radiological technicians), and other staff (e.g., receptionist); coordinators of centralized services for tobacco cessation at the component/subcomponent would also be eligible Current use of tobacco cessation medications Enrollment in another cessation program Participating in a current smoking cessation treatment (counseling or using nicotine replacement therapy [NRT], bupropion, or varenicline) Note: additional contraindications for individual nicotine replacement therapies and drugs (bupropion, or varenicline) are embedded within each study component to further screen participants when smoking cessation options are being considered Smoking cessation treatment use in past days Referred to MSKs Tobacco Cessation Program Patient's current participation in a tobacco cessation program Not engaged in smoking cessation treatment other than the MD Anderson Cancer Center (MDACC) Tobacco Treatment Program Subject considered by the investigator an unsuitable candidate for receipt of a smoking cessation treatment or unstable to be followed up throughout the entire duration of the study Current use of tobacco cessation medications. Taking any smoking cessation medications (e.g. varenicline, bupropion, nicotine replacement therapies) at the start of the study Following good clinical practice guidelines, be medically suitable for one or more pharmacotherapies for smoking cessation including NRT, bupropion or varenicline, at provider discretion. Current enrollment or plans to enroll in another smoking cessation program in the next months. Unwilling to refrain from other nicotine substitutes (i.e., over-the-counter [OTC] or prescription medication for smoking cessation) or smoking cessation treatments in the next months. Current use of certain medications: () Smoking cessation medications (meds) (last days), i.e., Wellbutrin, bupropion, Zyban, NRT, Chantix. Not currently enrolled in a face-to-face smoking cessation program Currently enrolled in an in-person cessation program Used smoking cessation medications within the past three months Are currently enrolled in a smoking cessation program Current use of medications with smoking cessation efficacy Current enrollment or plans to enroll in another smoking cessation program in the next months Plan to use other nicotine substitutes (i.e., over-the-counter [OTC] or prescription medication for smoking cessation) or smoking cessation treatments in the next months Interested in participating in a cessation program Currently participating in a smokeless tobacco cessation study Not currently enrolled in a face-to-face smoking cessation program Patients currently using a smoking cessation medication any medications prescribed to help with smoking cessation except short acting nicotine replacement therapy (NRT): gum, lozenges, spray, inhalers Seeking treatment for smoking cessation Agree to participate in this randomized smoking cessation trial with follow up assessments up to months Active use or recent use (=< to month) of medication or e-cigarettes for nicotine dependence/smoking cessation, or use of e-cigarettes for more than days in the prior month Received cessation treatment (including cessation counseling, NRT, bupropion, or varenicline) in past months; Current enrollment or plans to enroll in another smoking cessation program in the next months Plan to use other nicotine substitutes (i.e., over-the-counter [OTC] or prescription medication for smoking cessation) or smoking cessation treatments in the next months Used other smoking cessation medications within the past three months SMOKING CESSATION SUB-STUDY: Written informed consent will be obtained by trained study personnel from all participants Interested in participating in a cessation program Already participating in a smoking cessation intervention study STUDY II: Not currently enrolled in a face-to-face smoking cessation program Current participation in a cancer intervention prevention study, except for smoking cessation Other types of tobacco, NRT, smoking cessation medications Currently using smokeless tobacco, electronic nicotine delivery systems (ENDS), nicotine replacement therapy, or other smoking cessation treatment Current use of other smoking cessation medications (e.g., Chantix or Zyban) Enrolled in another smoking cessation study Participation in a smoking cessation program in the past days Currently using nicotine replacement or other tobacco cessation products or intention to quit in next three months Use within the last month of nicotine replacement or other tobacco cessation products for purpose of quitting; situational use of nicotine replacement is not a reason for exclusion (to prevent undermining of cessation efforts) TOBACCO CESSATION COACHING Willingness to receive calls from others (i.e., coaches, navigators) to help them quit smoking and address barriers to cessation current use of any smoking cessation medications current enrollment in a smoking cessation treatment study